Solventless medical cannabis, released under §52a AMG.

Solventless extracts, by design

Nexopharm works exclusively with solventless extracts — ice-water concentrates, dry-sift, and rosin pressed under heat and pressure. Hydrocarbon extraction (butane, propane, hexane) is excluded by specification, so residual solvents are never a release concern.

These extracts serve as the active pharmaceutical ingredient base for pharmacy-compounded formulations, including pastilles, inhalation preparations, and capsules. Every batch is accompanied by a full Ph. Eur. analytical panel and released by our Qualified Person under §52a AMG.

Strain Hunter Tour — flower selection on-site, every quarter

Flower is selected by hand. Each quarter, the Nexopharm remote audit team visits contracted cultivation facilities in person through our Strain Hunter Tour programme — assessing cultivar, batch quality, and compliance posture before any material enters the European supply chain.

Qualification follows GACP and EU-GMP-equivalent controls. Our audit team holds direct relationships with every cultivator we supply from, and selection decisions sit with the QP — not with brokers, not with the grower's own certificates.

Supply chain, by design confidential

Our cultivation partners operate under NDA, and Nexopharm does not disclose country of origin, regional identifiers, or facility names on public channels. This is a deliberate position — continuity of supply for German pharmacies depends on it.

What we disclose per batch is the full regulatory record: three-stage analytical verification (origin laboratory · pre-shipment ISO 17025 reference laboratory · incoming inspection at the EU-GMP processor), a Ph. Eur.-compliant CoA, chain-of-custody seals, and a Nexopharm batch identifier. Release decisions are signed off by Maryam Eftekhar, VP Regulatory and Qualified Person (§14 AMG).